Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed diagnosis of solid tumor~* treatment with anti-EGFR antibodies or TKIs~* first onset of severe pruritus during treatment (≥7 on Visual Analogue Scale (VAS) score)~Exclusion Criteria:~* oral treatment with antimycotics during 4 weeks preceding enrolment~* topical treatment during the previous 2 weeks~* concomitant,chronic renal or hepatic insufficiency , skin infection or dermatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: OTHER): Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
- Aprepitant after anti-itch standard therapy (Type: OTHER): Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week

Based on this trial design, predict the completion outcome and termination type (if applicable).